Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech companies publish some of the most technical disclosures on EDGAR, and Zevra Therapeutics is no exception. R&D expense swings tied to rare-disease trials, updates on FDA orphan-drug designations, and dilution from financing rounds all live inside 10-K, 10-Q, and 8-K forms that regularly top 200 pages. If you have ever typed “how do I read Zevra Therapeutics’ 10-K?” this page delivers Zevra Therapeutics SEC filings explained simply.
Stock Titan’s AI parses every line the moment it hits the tape, then surfaces what matters. Need the latest Zevra Therapeutics quarterly earnings report 10-Q filing? We highlight trial-spend by program and cash runway in plain English. Curious about Zevra Therapeutics insider trading Form 4 transactions before a data release? Get Zevra Therapeutics Form 4 insider transactions real-time alerts. Our platform also tags Zevra Therapeutics 8-K material events explained and turns them into concise summaries, so you can focus on decision-making instead of document hunting.
Drill deeper with our AI-powered tools:
- Zevra Therapeutics annual report 10-K simplified – see pipeline status, orphan-drug exclusivity timelines, and revenue assumptions in minutes.
- Zevra Therapeutics earnings report filing analysis – track quarter-over-quarter cash burn and partnership revenue.
- understanding Zevra Therapeutics SEC documents with AI – tap sectional notes that translate accounting jargon.
- Zevra Therapeutics executive stock transactions Form 4 – monitor how leadership reacts to pivotal trial milestones.
- Zevra Therapeutics proxy statement executive compensation – decode incentive structures tied to clinical success.
All filings update in real time, are searchable by keyword, and come with exportable data tables—because biotech diligence should be precise, not painful.
Zevra Therapeutics, Inc. reported that its Chief Financial Officer, Treasurer, and principal financial officer, R. LaDuane Clifton, has decided to resign effective December 31, 2025 to pursue other professional opportunities. The company and Mr. Clifton entered into a Separation Agreement under which he will receive separation benefits after his departure, including cash payments equal to 12 months of his annual base salary, an annual bonus equal to 40% of his base salary, up to 12 months of company-paid COBRA continuation coverage, and full vesting of his outstanding equity awards. These benefits are conditioned on his continued compliance with non-disparagement, confidentiality, non-competition, and non-solicitation covenants. Zevra has begun a search process to identify a new chief financial officer and issued a press release describing these matters.
Zevra Therapeutics (ZVRA) reported sharply improved results in its Q3 2025 10-Q. Revenue rose to $26.1 million from $3.7 million a year ago, driven mainly by MIPLYFFA sales. The company posted a small net loss of $0.5 million for the quarter versus a $33.2 million loss last year.
For the nine months ended September 30, 2025, revenue reached $72.3 million, and net income was $71.1 million, aided by a $148.3 million gain from selling a priority review voucher. Results also reflect a $58.7 million intangible asset impairment and $11.7 million in inventory write-downs. MIPLYFFA generated $22.4 million in Q3 and $61.0 million year-to-date; OLPRUVA contributed $0.1 million in Q3 and $0.5 million year-to-date. The AZSTARYS license produced $1.2 million in Q3.
Liquidity strengthened: cash and cash equivalents were $54.4 million with $175.9 million in investment securities at fair value, and stockholders’ equity increased to $133.2 million. Long-term debt stood at $61.3 million under the 2024 term loan facility. As of November 3, 2025, 56,297,535 shares of common stock were outstanding.
Zevra Therapeutics (ZVRA) reported it has furnished a press release announcing financial results and corporate updates for the third quarter ended September 30, 2025. The company also scheduled a conference call and audio webcast for November 5, 2025 at 4:30 p.m. ET to discuss these updates.
The press release is furnished as Exhibit 99.1 and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly specified.
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (ZVRA), reported equity transactions on
ZEVRA THERAPEUTICS, INC. (ZVRA) filed a Form 144 disclosing a proposed sale of 19,500 common shares by an insider through Morgan Stanley Smith Barney LLC on
The securities were acquired as Restricted Stock Units and the acquisition and planned sale date are both reported as
Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.
Alvin Shih, a director of Zevra Therapeutics (ZVRA), purchased 20,000 shares of the company's common stock on 09/12/2025 at a weighted-average price of $7.89 per share. The Form 4 shows the transaction was reported as an acquisition and that the reporting person beneficially owns 20,000 shares following the purchase. The footnote states the $7.89 figure is a weighted average from multiple trades priced between $7.85 and $7.90 and that detailed allocation of trades is available on request. The filing was signed by an attorney-in-fact on behalf of Mr. Shih.
Zevra Therapeutics director John B. Bode acquired 5,000 shares of the company's common stock on 08/19/2025 at a reported price of $9.165 per share. After the purchase he beneficially owns 45,000 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/20/2025.
Zevra Therapeutics reported a net income of $74.7 million for the quarter ended June 30, 2025, driven largely by a $148.3 million gain on the sale of a transferable priority review voucher (PRV). Product revenue rose to $25.9 million for the quarter and $46.3 million year-to-date, led by MIPLYFFA sales of $21.5 million in the quarter.
The balance sheet strengthened with $47.7 million in cash and approximately $170.0 million in fair-value securities, bringing total assets to $256.3 million and stockholders' equity to $117.2 million. Material charges included a $58.7 million intangible-asset impairment related to OLPRUVA and an $11.7 million inventory write-down. Long-term debt was $60.7 million. The company disclosed ongoing litigation concerning the AZSTARYS license agreement.
Zevra Therapeutics announced it issued a press release on August 12, 2025 reporting financial results and corporate updates for the quarter ended June 30, 2025. The company scheduled a conference call and audio webcast for Tuesday, August 12, 2025 at 4:30 p.m. ET to discuss those results. The press release is furnished as Exhibit 99.1 to this Form 8-K and is explicitly furnished, not filed, so it is not incorporated by reference into Zevra's other securities filings. The Form 8-K does not include financial statements or tables within the filing itself.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
